![]() ![]() ![]() In fact, we have the most experience in the region in performing minimally invasive/robotic procedures for complex urologic conditions and are considered a national leader in these techniques.įor example, 90 percent of our procedures for kidney cancer are performed minimally invasively. Our team of highly experienced, fellowship-trained urologists, all of whom are on the faculty of Harvard Medical School, provides comprehensive, patient-centered care and the most advanced treatments - including the latest minimally invasive/robotic and laser ablation procedures - for men and women with all types of urologic conditions. Choosing BIDMC urologic surgery means you are choosing the most highly qualified and skilled urologic surgeons in New England. Welcome to the Division of Urologic Surgery at BIDMC, which provides patient care at our flagship hospital in Boston as well as Beth Israel Deaconess Hospital-Needham, Beth Israel Deaconess Hospital-Milton and Beth Israel Deaconess HealthCare-Chestnut Hill. ![]() Robotic-Assisted Nephroureterectomy (Removal of Kidney and Ureter)Įxtracorporeal Shock Wave Lithotripsy (ESWL) All rights reserved.More Within Urologic Surgery Urologic Surgeryīladder Tumor: Cystoscopic Resection (TURBT) This is an Open Access article under the CC BY 4.0 license. The ShangRing could be used by health systems and international organisations to further scale up EIMC across sub-Saharan Africa.Ĭopyright © 2022 The Author(s). Use of the ShangRing device for EIMC showed safety, achieved high caregiver satisfaction, and did not differ from the Mogen clamp in other key measures. No treatment-related deaths were reported. Rates of moderate and severe AEs were similar between both groups (29 in the ShangRing group vs 30 in the Mogen clamp group difference -0♱% one-sided 95% CI upper limit of 1♷% p=0♸9). The most common treatment-related AE was intraoperative pain (Neonatal Infant Pain Scale score ≥5), with 19 (2♸%) events in the ShangRing and 23 (3♳%) in the Mogel clamp group. 43 (6♲%) adverse events were observed in the ShangRing group and 61 (8♹%) in the Mogen clamp group (p=0♰78). 689 (50♰%) infants were randomly assigned to undergo EIMC by ShangRing and 689 (50♰%) by Mogen clamp. This trial is registered with Clinical.īetween Sept 17, 2018, and Dec 20, 2019, a total of 1420 infants were assessed for eligibility, of whom 1378 (97♰%) were enrolled. The primary endpoint was safety, defined as the number and severity of adverse events (AEs), analysed in the intention-to-treat population (all infants who underwent an EIMC procedure) with a non-inferiority margin of 2% for the difference in moderate and severe AEs. Infants were randomly assigned (1:1) by a computer-generated text message service to undergo EIMC by either the ShangRing or the Mogen clamp. In this multicentre, non-inferiority, open-label, randomised controlled trial, we enrolled healthy male infants (aged <60 days), with a gestational age of at least 37 weeks and a birthweight of at least 2♵ kg, from 11 community and referral centres in Kenya, Tanzania, and Uganda. We aimed to investigate the safety and efficacy of the ShangRing versus the Mogen clamp for EIMC in infants across eastern sub-Saharan Africa. The ShangRing, a circumcision device prequalified by WHO, is approved for use in adults and adolescents and requires topical anaesthesia only. Use of medical devices represents a unique opportunity to facilitate scale-up of early infant male circumcision (EIMC) across sub-Saharan Africa.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |